Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galactooligosaccharides + inulin is a combination of two well-studied prebiotic fibers. Both are non-digestible carbohydrates that selectively stimulate the growth and activity of beneficial gut bacteria, particularly Bifidobacteria and Lactobacilli. This combination has been investigated for its synergistic effects on gut health, immune modulation, and potential chemopreventive properties against colorectal cancer. In animal models, the combined use of GOS and inulin demonstrated greater inhibition of precancerous lesions (aberrant crypt foci) than either component alone[2]. In humans, these prebiotics are used to support digestive health, relieve constipation, modulate blood sugar levels (especially relevant for diabetes), promote mineral absorption (notably calcium), improve stool frequency/consistency, and potentially reduce risk factors associated with colon cancer[3][5][6]. The mechanism involves fermentation by colonic bacteria to produce short-chain fatty acids (SCFAs), which contribute to improved mucosal health and immune regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galactooligosaccharides + inulin.